Breast Cancer Trial, Not Yet RecruitingNCT07527819Sponsor: Peter MacCallum Cancer Centre, AustraliaCondition: Breast Cancer
Printed from Voxsanity (voxsanity.com.au) — NCT07527819 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Not Yet RecruitingNot Applicable🇦🇺 Australian site
voxsanity.com.au ·
Eligibility summary from public government registries ·
18 August 2026 ·
not medical advice
Who may and may not be able to join
AI generated eligibility summary.
Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source.
How we use AI
Who may be able to join
The person has signed a written consent form specific to this trial (called the FERTILE Patient Information and Consent form).
The person has been diagnosed with early-stage triple-negative breast cancer (TNBC), as determined by their treating doctor.
The person is female and between 18 and 42 years of age.
The person is planned to receive at least one round of pre-surgery chemotherapy combined with a type of cancer immunotherapy drug (such as pembrolizumab, atezolizumab, durvalumab, or nivolumab).
The person is planned to receive a hormone-protecting injection called a GnRH agonist alongside their pre-surgery chemotherapy.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
The person has previously had both ovaries removed, or their ovaries have been shut down through radiation treatment.
The person has already received immunotherapy or chemotherapy before being registered for this trial.
The person is currently receiving or is planned to receive a type of hormone treatment called adjuvant endocrine therapy (note: receiving a GnRH agonist to protect ovarian function does not count as a reason to exclude someone).
The person has gone through menopause, as assessed by the treating doctor.
The person has psychological, social, geographical, or other circumstances where, in the trial doctor's opinion, taking part would not be in the person's best interest or could affect the reliability of the trial assessments.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 17 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
Chris O'Brien Lifehouse, Camperdown, New South Wales
Mater Hospital Sydney, Sydney, New South Wales
Lyell McEwin Hospital, Adelaide, South Australia
Icon Cancer Centre, Hobart, Tasmania
Eastern Health, Box Hill, Victoria
Monash Health, Clayton, Victoria
Peter MacCallum Cancer Centre, Melbourne, Victoria
Royal Melbourne Hospital, Melbourne, Victoria
Sir Charles Gairdner Hospital, Nedlands, Washington
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Voxsanity
Clinical trials and treatments, explained plainly · voxsanity.com.au
Date:
To: My Doctor
Re: Clinical trial enquiry
I am writing to enquire about the following clinical trial which may be relevant to my care:
Trial: NCT07527819
Sponsor: Peter MacCallum Cancer Centre, Australia
Phase: Not Applicable
Status: Not Yet Recruiting
Condition: Breast Cancer
Trial contact: +61 3 8559 5000
More information: https://clinicaltrials.gov/study/NCT07527819
Eligibility summary (AI generated)
Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.
Who may be able to join
The person has signed a written consent form specific to this trial (called the FERTILE Patient Information and Consent form).
The person has been diagnosed with early-stage triple-negative breast cancer (TNBC), as determined by their treating doctor.
The person is female and between 18 and 42 years of age.
The person is planned to receive at least one round of pre-surgery chemotherapy combined with a type of cancer immunotherapy drug (such as pembrolizumab, atezolizumab, durvalumab, or nivolumab).
The person is planned to receive a hormone-protecting injection called a GnRH agonist alongside their pre-surgery chemotherapy.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
The person has previously had both ovaries removed, or their ovaries have been shut down through radiation treatment.
The person has already received immunotherapy or chemotherapy before being registered for this trial.
The person is currently receiving or is planned to receive a type of hormone treatment called adjuvant endocrine therapy (note: receiving a GnRH agonist to protect ovarian function does not count as a reason to exclude someone).
The person has gone through menopause, as assessed by the treating doctor.
The person has psychological, social, geographical, or other circumstances where, in the trial doctor's opinion, taking part would not be in the person's best interest or could affect the reliability of the trial assessments.
Important: Always verify eligibility with the trial site directly before applying.
Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.
This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 17 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.
Trial details
Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
Peter MacCallum Cancer Centre, Australia
Registry
ClinicalTrials.gov
Start date
8 April 2026
Est. completion
1 April 2031
Where this trial is recruiting
🇦🇺 Australia
9 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Premature Ovarian Insufficiency (POI) at 24 months after cessation of neoadjuvant chemotherapy-ICI
Can't join this trial?
Expanded access pathways
If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.
Data last synced from ClinicalTrials.gov: 17 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.
Analytics cookies are set only if you accept. Advertising runs with personalisation
permanently off and is not changed by this choice — see our
Privacy Policy.